Isabel Badell

Isabel Badell

Auto-generated profile, based on publicly available information

Isabel Badell

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2011 in Blood
Verified
Journal Article
Open access
PDF file
MCMaria Castella
Maria Castella
RPRoser Pujol
Roser Pujol
ECElsa Callén
Elsa Callén
JTJuan P. Trujillo
Juan P. Trujillo
JCJosé A. Casado
José A. Casado
Jordi SurrallésJordi Surrallés
Jordi Surrallés
Fanconi anemia is characterized by congenital abnormalities, bone marrow failure, and cancer predisposition. To investigate the origin, functional role, and clinical impact of FANCA mutations, we determined a FANCA mutational spectrum with 130 pathogenic alleles. Some of these mutations were further characterized for their distribution in populations, mode of emergence, or functional consequences at cellular and clinical level. The world most frequent FANCA mutation is not the result of a mutational “hot-spot” but results from worldwide dissemination of an ancestral Indo-European mutation. We provide molecular evidence that total absence of FANCA in humans does not reduce embryonic viability, as the observed frequency of mutation carriers in the Gypsy population equals the expected by Hardy-Weinberg equilibrium. We also prove that long distance Alu-Alu recombination can cause Fanconi anemia by originating large interstitial deletions involving FANCA and 2 adjacent genes. Finally, we show that all missense mutations studied lead to an altered FANCA protein that is unable to relocate to the nucleus and activate the FA/BRCA pathway. This may explain the observed lack of correlation between type of FANCA mutation and cellular phenotype or clinical severity in terms of age of onset of hematologic disease or number of malformations.

10 November 2005 in Leukemia
Verified
Journal Article
Open access
PDF file
GPG Perea
G Perea
ALAdriana Lasa
Adriana Lasa
AAA Aventín
A Aventín
ADA Domingo
A Domingo
NVN Villamor
N Villamor
FSFor The Grupo Cooperativo Para el Estudio Y Tratamiento de Las Leucemias Agudas Y Mielodisplasias (Cetlam). Spain
For The Grupo Cooperativo Para el Estudio Y Tratamiento de Las Leucemias Agudas Y Mielodisplasias (Cetlam). Spain
Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline- and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients, 28 harboring a t(8;21) and 27 an inv(16), including one case with a novel CBFbeta/MYH11 transcript. A total of 31% (n=17) of CR patients relapsed: seven with t(8;21) and 10 with inv(16). The mean amount of minimal residual disease (MRD) detected by FC in relapsed and nonrelapsed patients was markedly different: 0.3 vs 0.08% (P=0.002) at the end of treatment. The mean number of fusion transcript copies/ABLx104 also differed between relapsed and non-relapsed patients: 2385 vs 122 (P=0.001) after induction, 56 vs 7.6 after intensification (P=0.0001) and 75 vs 3.3 (P=0.0001) at the end of chemotherapy. Relapses were more common in patients with FC MRD level >0.1% at the end of treatment than in patients with ⩽0.1%: cumulative incidence of relapse (CIR) was 67 and 21% (P=0.03), respectively. Likewise, using RQ-PCR, a cutoff level of >10 copies at the end of treatment correlated with a high risk of relapse: CIR was 75% for patients with RQ-PCR >10 compared to 21% for patients with RQ-PCR levels ⩽10 (P=0.04). Combined use of FC and RQ-PCR may improve MRD detection, and provide useful clinical information on relapse kinetics in AML patients.

22 March 2012 in Blood
Verified
Journal Article
Closed access
PDF file
JSJan Styczyński
Jan Styczyński
ABAdriana Balduzzi
Adriana Balduzzi
LGLidia Gil
Lidia Gil
MLMyriam Labopin
Myriam Labopin
RHRose-Marie Hamladji
Rose-Marie Hamladji
CPChristina Peters
Christina Peters
We investigated prospectively factors influencing the safety of hematopoietic stem cell (HSC) collection in 453 pediatric donors. The children in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy. A large variability in approach to donor issues was observed between the participating centers. Significant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, duration of hospital stay, and iron supplementation; however, differences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between the 2 procedures. The most common adverse event was pain, reported mainly by older children after BM harvest, but also observed after central venous catheter (CVC) placement for PBSC collection. With regard to severe adverse events, one patient (0.7%) developed a pneumothorax with hydrothorax after CVC placement for PBSC collection. The risk of allotransfusion after BM harvest was associated with a donor age of < 4 years and a BM harvest volume of > 20 mL/kg. Children < 4 years were at higher risk than older children for allotransfusion after BM harvest and there was a higher risk of complications from CVC placement before apheresis. We conclude that PBSC and BM collection are safe procedures in children.

10 October 2017 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
ELE. Llaudet‐Planas
E. Llaudet‐Planas
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
VRV. Rizzuto
V. Rizzuto
PGP. Gómez‐Ramírez
P. Gómez‐Ramírez
JSJulián Sevilla
Julián Sevilla
MMM. M. Mañú‐Pereira
M. M. Mañú‐Pereira

1 February 2002 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ECElsa Callén
Elsa Callén
ESEnrique Samper
Enrique Samper
MRMaría J. Ramírez
María J. Ramírez
ACAmadeu Creus
Amadeu Creus
RMRicard Marcos
Ricard Marcos
Jordi SurrallésJordi Surrallés
Jordi Surrallés
Fanconi anemia (FA) is a rare genetic disease characterized by chromosome instability, progressive pancytopenia and cancer susceptibility. Telomeres are intimately related to chromosome stability and play an important role in organismal viability at the hematological level. Since previous works suggested an accelerated shortening of telomeres in FA, we have studied several markers of telomere integrity and function in FA patients and age-matched controls to get insights into the mechanisms and consequences of telomere erosion in FA. A higher frequency of extra-chromosomic TTAGGG signals and of chromosome ends with undetectable TTAGGG repeats was observed in FA cells by fluorescence in situ hybridization (FISH), suggesting intensive breakage at telomeric sequences. This was proven by measuring the frequency of excess of telomeric signals per cell, which was 2.8-fold higher in FA. Consistent with previous reports, quantitative FISH analysis showed an accelerated telomere shortening of 0.68 kb in FA, which occurred concurrently in both chromosome arms in a similar magnitude. Our data therefore suggest that the telomere erosion in FA is caused by a higher rate of breakage at TTAGGG sequences in vivo in differentiated cells, in addition to mere replicative shortening during lymphocyte proliferation. Consistent with impaired telomeres in FA patients, we observed a >10-fold increase in chromosome end fusions in FA compared to normal controls. This observation was independent of TRF2, a telomere binding factor that protects human telomeres from end fusions, since immunohistochemistry studies in FA cell lines and corrected counterparts by retrovirus-mediated transfer of FANCA and FANCD2 cDNA showed that a functional FA pathway is not required for telomere binding of TRF2.

3 September 2009 in Blood
Verified
Journal Article
Open access
PDF file
ACAlexander Claviez
Alexander Claviez
CCCarme Canals
Carme Canals
DDDaan Dierickx
Daan Dierickx
JSJerry Stein
Jerry Stein
IBIsabel Badell
Isabel Badell
NSNorbert Schmitz
Norbert Schmitz
Ninety-one children and adolescents 18 years or younger after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed or refractory Hodgkin lymphoma (HL) were analyzed. Fifty-one patients received reduced intensity conditioning (RIC); 40 patients received myeloablative conditioning (MAC). Nonrelapse mortality (NRM) at 1 year was 21% (± 4%), with comparable results after RIC or MAC. Probabilities of relapse at 2 and 5 years were 36% (± 5%) and 44% (± 6%), respectively. RIC was associated with an increased relapse risk compared with MAC; most apparent beginning 9 months after HSCT (P = .01). Progression-free survival (PFS) was 40% (± 6%) and 30% (± 6%) and overall survival (OS) was 54% (± 6%) and 45% (± 6%) at 2 and 5 years, respectively. Disease status at HSCT was predictive of PFS in multivariate analysis (P < .001). Beyond 9 months, PFS after RIC was lower compared with MAC (P = .02). Graft-versus-host disease did not affect relapse rate and PFS. In conclusion, children and adolescents with recurring HL show reasonable results with allogeneic HSCT. Especially patients allografted in recent years with good performance status and chemosensitive disease show highly encouraging results (PFS: 60% ± 27%, OS: 83% ± 15% at 3 years). Because relapse remains the major cause of treatment failure, additional efforts to improve disease control are necessary.